Discovery of Thieno[2,3-<i>e</i>]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability-Reference-Cited by-同舟云学术

Discovery of Thieno[2,3-e]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability

Published:2022-03-31 Issue:7 Volume:65 Page:5724-5750
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lu Zhengyu¹²,Cao Yangzhi¹²,Zhang Dan¹,Meng Xin¹,Guo Bin¹²,Kong Deyu³,Yang Yushe¹²^ORCID

Affiliation:

1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

2. School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China

3. Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China

Funder

Youth Innovation Promotion Association of the Chinese Academy of Sciences

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00008

Reference62 articles.

1. Tamoxifen: a most unlikely pioneering medicine

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020, 2020. https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/.

4. Biological subtypes of breast cancer: Prognostic and therapeutic implications

5. Molecular Pathology of Breast Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct Introduction of the 1‐Fluorocyclopropyl Group via Stille Cross‐Coupling – A Way of Getting Around Per‐ and Polyfluoroalkyl Substances (PFASs);Advanced Synthesis & Catalysis;2024-07-18

2. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023);Expert Opinion on Therapeutic Patents;2024-05-03

3. Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer;Acta Pharmaceutica Sinica B;2023-12

4. Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment;Current Topics in Medicinal Chemistry;2023-10

5. Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future;Frontiers in Pharmacology;2023-09-21